• Melflufen

    Melflufen (INN melphalan flufenamide) is a first in class peptide-drug conjugate (PDC) that targets aminopeptidases and rapidly releases alkylating agents into tumor cells. Melflufen is rapidly taken up by myeloma cells due to its high lipophilicity and is immediately hydrolyzed by peptidases to release an entrapped hydrophilic alkylator payload.
    Melflufen is an investigational drug and is not approved for commercial use.

  • Oncopeptides

    Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company is focusing on the development of the lead product candidate melflufen, a first in class peptide-drug conjugate (PDC) that targets aminopeptidases and rapidly releases alkylating agents into tumor cells.

Audiocast regarding operational update Q2 2020

Oncopeptides held an operational update August 26, 2020. It was presented by CEO Marty J Duvall, CSO Jakob Lindberg and CFO Anders-Martin-Löf. The presentation was recorded.

Audiocast regarding operational update Q1 2020

Oncopeptides held an operational update Tuesday May 26, 2020. It was presented by CEO Jakob Lindberg and members of Oncopeptides management team. The presentation was recorded.